These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 16842382)

  • 1. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.
    Widmer N; Decosterd LA; Csajka C; Leyvraz S; Duchosal MA; Rosselet A; Rochat B; Eap CB; Henry H; Biollaz J; Buclin T
    Br J Clin Pharmacol; 2006 Jul; 62(1):97-112. PubMed ID: 16842382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
    Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.
    Delbaldo C; Chatelut E; Ré M; Deroussent A; Séronie-Vivien S; Jambu A; Berthaud P; Le Cesne A; Blay JY; Vassal G
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6073-8. PubMed ID: 17062683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients.
    Gambacorti-Passerini C; Zucchetti M; Russo D; Frapolli R; Verga M; Bungaro S; Tornaghi L; Rossi F; Pioltelli P; Pogliani E; Alberti D; Corneo G; D'Incalci M
    Clin Cancer Res; 2003 Feb; 9(2):625-32. PubMed ID: 12576428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype.
    Gurney H; Wong M; Balleine RL; Rivory LP; McLachlan AJ; Hoskins JM; Wilcken N; Clarke CL; Mann GJ; Collins M; Delforce SE; Lynch K; Schran H
    Clin Pharmacol Ther; 2007 Jul; 82(1):33-40. PubMed ID: 17495881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.
    Teng JF; Mabasa VH; Ensom MH
    Ther Drug Monit; 2012 Feb; 34(1):85-97. PubMed ID: 22215488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.
    Petain A; Kattygnarath D; Azard J; Chatelut E; Delbaldo C; Geoerger B; Barrois M; Séronie-Vivien S; LeCesne A; Vassal G;
    Clin Cancer Res; 2008 Nov; 14(21):7102-9. PubMed ID: 18981009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics of Imatinib and its application to the therapeutic drug monitoring: Middle East CML population.
    Ansari M; Kalantary-Khandani B; Pardakhty A; Safavi M; Mosavi N; Mohajeri E
    Gulf J Oncolog; 2016 Sep; 1(22):26-36. PubMed ID: 28191803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of imatinib mesylate.
    Levêque D; Maloisel F
    In Vivo; 2005; 19(1):77-84. PubMed ID: 15796158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed?
    Gandia P; Arellano C; Lafont T; Huguet F; Malard L; Chatelut E
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):531-6. PubMed ID: 23183914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.
    Peng B; Hayes M; Resta D; Racine-Poon A; Druker BJ; Talpaz M; Sawyers CL; Rosamilia M; Ford J; Lloyd P; Capdeville R
    J Clin Oncol; 2004 Mar; 22(5):935-42. PubMed ID: 14990650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring of plasma imatinib concentration for the effective treatment of CML patients.
    Tsutsumi Y; Kanamori H; Yamato H; Ehira N; Miura T; Kawamura T; Obara S; Tanaka J; Asaka M; Imamura M; Masauzi N
    Leuk Res; 2004 Oct; 28(10):1117-8. PubMed ID: 15289027
    [No Abstract]   [Full Text] [Related]  

  • 13. [Serum α1-acid glycoprotein, imatinib concentration and efficacy in chronic myeloid leukemia patients].
    Zhong JS; Meng FY; Xu D; Dai M; Wei YQ; Zhou HS
    Zhonghua Yi Xue Za Zhi; 2011 Aug; 91(30):2120-3. PubMed ID: 22093988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.
    Schmidli H; Peng B; Riviere GJ; Capdeville R; Hensley M; Gathmann I; Bolton AE; Racine-Poon A;
    Br J Clin Pharmacol; 2005 Jul; 60(1):35-44. PubMed ID: 15963092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients.
    Streit F; Binder L; Hafke A; Brandhorst G; Braulke F; Haase D; Armbrust T; Cameron S; Ramadori G; Oellerich M; Walson P
    Ther Drug Monit; 2011 Oct; 33(5):632-43. PubMed ID: 21912334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia.
    Mahon FX; Molimard M
    Leuk Res; 2009 Aug; 33(8):1147-8; author reply 1149-50. PubMed ID: 19395027
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of St John's wort on imatinib mesylate pharmacokinetics.
    Frye RF; Fitzgerald SM; Lagattuta TF; Hruska MW; Egorin MJ
    Clin Pharmacol Ther; 2004 Oct; 76(4):323-9. PubMed ID: 15470331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome.
    Beumer JH; Natale JJ; Lagattuta TF; Raptis A; Egorin MJ
    Pharmacotherapy; 2006 Jul; 26(7):903-7. PubMed ID: 16803422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia.
    Di Paolo A; Polillo M; Capecchi M; Cervetti G; Baratè C; Angelini S; Guerrini F; Fontanelli G; Arici R; Ciabatti E; Grassi S; Bocci G; Hrelia P; Danesi R; Petrini M; Galimberti S
    Pharmacogenomics J; 2014 Aug; 14(4):328-35. PubMed ID: 24589908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of imatinib targeted delivery in human leukocytes.
    Kralj E; Žakelj S; Trontelj J; Pajič T; Preložnik Zupan I; Černelč P; Ostanek B; Marc J; Kristl A
    Eur J Pharm Sci; 2013 Sep; 50(1):123-9. PubMed ID: 23643738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.